Which has better valuation & earnings, KRYS or ZLAB?

Krystal Biotech has higher earnings, but lower revenue than Zai Lab. Zai Lab is trading at a lower price-to-earnings ratio than Krystal Biotech, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Krystal Biotech $389.13M 26.00 $204.83M $7.98 42.83 Zai Lab $460.16M 6.54 -$175.54M -$1.71 N/A

Is KRYS or ZLAB more profitable?

Krystal Biotech has a net margin of 54.82% compared to Zai Lab's net margin of -41.86%. Krystal Biotech's return on equity of 19.34% beat Zai Lab's return on equity. Company Net Margins Return on Equity Return on Assets Krystal Biotech 54.82% 19.34% 17.65% Zai Lab -41.86% -27.43% -16.72%

Does the media favor KRYS or ZLAB?

In the previous week, Krystal Biotech had 4 more articles in the media than Zai Lab. MarketBeat recorded 6 mentions for Krystal Biotech and 2 mentions for Zai Lab. Krystal Biotech's average media sentiment score of 1.27 beat Zai Lab's score of -0.14 indicating that Krystal Biotech is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Krystal Biotech 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Zai Lab 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better earnings & valuation, ABVX or ZLAB?

Zai Lab has higher revenue and earnings than Abivax. Abivax is trading at a lower price-to-earnings ratio than Zai Lab, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Abivax N/A N/A -$380.27M -$6.06 N/A Zai Lab $460.16M 6.54 -$175.54M -$1.71 N/A

Is ABVX or ZLAB more profitable?

Abivax has a net margin of 0.00% compared to Zai Lab's net margin of -41.86%. Zai Lab's return on equity of -27.43% beat Abivax's return on equity. Company Net Margins Return on Equity Return on Assets Abivax N/A -91.69% -71.96% Zai Lab -41.86% -27.43% -16.72%

Does the media prefer ABVX or ZLAB?

In the previous week, Abivax had 21 more articles in the media than Zai Lab. MarketBeat recorded 23 mentions for Abivax and 2 mentions for Zai Lab. Zai Lab's average media sentiment score of -0.14 beat Abivax's score of -0.20 indicating that Zai Lab is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Abivax 1 Very Positive mention(s) 2 Positive mention(s) 10 Neutral mention(s) 5 Negative mention(s) 1 Very Negative mention(s) Neutral Zai Lab 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to ZLAB or PTGX?

In the previous week, Zai Lab had 1 more articles in the media than Protagonist Therapeutics. MarketBeat recorded 2 mentions for Zai Lab and 1 mentions for Protagonist Therapeutics. Protagonist Therapeutics' average media sentiment score of 1.76 beat Zai Lab's score of -0.14 indicating that Protagonist Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zai Lab 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Protagonist Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Which has higher valuation and earnings, ZLAB or KYMR?

Zai Lab has higher revenue and earnings than Kymera Therapeutics. Kymera Therapeutics is trading at a lower price-to-earnings ratio than Zai Lab, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Zai Lab $460.16M 6.54 -$175.54M -$1.71 N/A Kymera Therapeutics $105M 91.44 -$311.35M -$3.24 N/A

Is ZLAB or KYMR more profitable?

Zai Lab has a net margin of -41.86% compared to Kymera Therapeutics' net margin of -285.33%. Kymera Therapeutics' return on equity of -21.22% beat Zai Lab's return on equity. Company Net Margins Return on Equity Return on Assets Zai Lab -41.86% -27.43% -16.72% Kymera Therapeutics -285.33% -21.22% -19.21%

Does the media refer more to ZLAB or KYMR?

In the previous week, Kymera Therapeutics had 4 more articles in the media than Zai Lab. MarketBeat recorded 6 mentions for Kymera Therapeutics and 2 mentions for Zai Lab. Kymera Therapeutics' average media sentiment score of 0.81 beat Zai Lab's score of -0.14 indicating that Kymera Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zai Lab 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Kymera Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to ZLAB or PRAX?

In the previous week, Praxis Precision Medicines had 1 more articles in the media than Zai Lab. MarketBeat recorded 3 mentions for Praxis Precision Medicines and 2 mentions for Zai Lab. Praxis Precision Medicines' average media sentiment score of 0.45 beat Zai Lab's score of -0.14 indicating that Praxis Precision Medicines is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zai Lab 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Praxis Precision Medicines 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Zai Lab (ZLAB) Competitors

$26.44 +0.03 (+0.11%)

Closing price 09/23/2026 04:00 PM Eastern

Extended Trading

$25.50 -0.94 (-3.56%)

As of 05:03 AM Eastern

Compare

ZLAB vs. KRYS, ABVX, PTGX, KYMR, and PRAX

Should you buy Zai Lab stock or one of its competitors? Zai Lab's main competitors and comparable companies include Krystal Biotech (KRYS), Abivax (ABVX), Protagonist Therapeutics (PTGX), Kymera Therapeutics (KYMR), and Praxis Precision Medicines (PRAX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Zai Lab compare to Krystal Biotech?

Krystal Biotech (NASDAQ:KRYS) and Zai Lab (NASDAQ:ZLAB) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, dividends, risk, institutional ownership, valuation, analyst recommendations, earnings and media sentiment.

Krystal Biotech has a net margin of 54.82% compared to Zai Lab's net margin of -41.86%. Krystal Biotech's return on equity of 19.34% beat Zai Lab's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Krystal Biotech	54.82%	19.34%	17.65%
Zai Lab	-41.86%	-27.43%	-16.72%

Krystal Biotech presently has a consensus price target of $365.80, suggesting a potential upside of 7.04%. Zai Lab has a consensus price target of $37.25, suggesting a potential upside of 40.89%. Given Zai Lab's higher possible upside, analysts clearly believe Zai Lab is more favorable than Krystal Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Krystal Biotech	0 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.92
Zai Lab	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71

86.3% of Krystal Biotech shares are held by institutional investors. Comparatively, 41.7% of Zai Lab shares are held by institutional investors. 13.1% of Krystal Biotech shares are held by insiders. Comparatively, 4.9% of Zai Lab shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, Krystal Biotech had 4 more articles in the media than Zai Lab. MarketBeat recorded 6 mentions for Krystal Biotech and 2 mentions for Zai Lab. Krystal Biotech's average media sentiment score of 1.27 beat Zai Lab's score of -0.14 indicating that Krystal Biotech is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Krystal Biotech	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Zai Lab	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Krystal Biotech has a beta of 0.54, meaning that its stock price is 46% less volatile than the broader market. Comparatively, Zai Lab has a beta of 0.83, meaning that its stock price is 17% less volatile than the broader market.

Krystal Biotech has higher earnings, but lower revenue than Zai Lab. Zai Lab is trading at a lower price-to-earnings ratio than Krystal Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Krystal Biotech	$389.13M	26.00	$204.83M	$7.98	42.83
Zai Lab	$460.16M	6.54	-$175.54M	-$1.71	N/A

Summary

Krystal Biotech beats Zai Lab on 13 of the 16 factors compared between the two stocks.

How does Zai Lab compare to Abivax?

Abivax (NASDAQ:ABVX) and Zai Lab (NASDAQ:ZLAB) are both mid-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, profitability, analyst recommendations, dividends, institutional ownership, media sentiment, valuation and risk.

In the previous week, Abivax had 21 more articles in the media than Zai Lab. MarketBeat recorded 23 mentions for Abivax and 2 mentions for Zai Lab. Zai Lab's average media sentiment score of -0.14 beat Abivax's score of -0.20 indicating that Zai Lab is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Abivax	1 Very Positive mention(s)	2 Positive mention(s)	10 Neutral mention(s)	5 Negative mention(s)	1 Very Negative mention(s)	Neutral
Zai Lab	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Abivax presently has a consensus price target of $156.69, suggesting a potential upside of 66.46%. Zai Lab has a consensus price target of $37.25, suggesting a potential upside of 40.89%. Given Abivax's stronger consensus rating and higher possible upside, equities research analysts plainly believe Abivax is more favorable than Zai Lab.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Abivax	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.88
Zai Lab	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71

Abivax has a beta of 0.96, suggesting that its stock price is 4% less volatile than the broader market. Comparatively, Zai Lab has a beta of 0.83, suggesting that its stock price is 17% less volatile than the broader market.

47.9% of Abivax shares are owned by institutional investors. Comparatively, 41.7% of Zai Lab shares are owned by institutional investors. 4.9% of Zai Lab shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Abivax has a net margin of 0.00% compared to Zai Lab's net margin of -41.86%. Zai Lab's return on equity of -27.43% beat Abivax's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Abivax	N/A	-91.69%	-71.96%
Zai Lab	-41.86%	-27.43%	-16.72%

Zai Lab has higher revenue and earnings than Abivax. Abivax is trading at a lower price-to-earnings ratio than Zai Lab, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Abivax	N/A	N/A	-$380.27M	-$6.06	N/A
Zai Lab	$460.16M	6.54	-$175.54M	-$1.71	N/A

Summary

Zai Lab beats Abivax on 8 of the 15 factors compared between the two stocks.

How does Zai Lab compare to Protagonist Therapeutics?

Zai Lab (NASDAQ:ZLAB) and Protagonist Therapeutics (NASDAQ:PTGX) are both mid-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, risk, dividends, profitability, earnings, institutional ownership, media sentiment and valuation.

41.7% of Zai Lab shares are owned by institutional investors. Comparatively, 98.6% of Protagonist Therapeutics shares are owned by institutional investors. 4.9% of Zai Lab shares are owned by insiders. Comparatively, 5.2% of Protagonist Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Zai Lab presently has a consensus target price of $37.25, suggesting a potential upside of 40.89%. Protagonist Therapeutics has a consensus target price of $147.13, suggesting a potential upside of 6.08%. Given Zai Lab's higher possible upside, equities research analysts plainly believe Zai Lab is more favorable than Protagonist Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zai Lab	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71
Protagonist Therapeutics	0 Sell rating(s)	2 Hold rating(s)	16 Buy rating(s)	0 Strong Buy rating(s)	2.89

In the previous week, Zai Lab had 1 more articles in the media than Protagonist Therapeutics. MarketBeat recorded 2 mentions for Zai Lab and 1 mentions for Protagonist Therapeutics. Protagonist Therapeutics' average media sentiment score of 1.76 beat Zai Lab's score of -0.14 indicating that Protagonist Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zai Lab	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Protagonist Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Zai Lab has a beta of 0.83, meaning that its share price is 17% less volatile than the broader market. Comparatively, Protagonist Therapeutics has a beta of 1.8, meaning that its share price is 80% more volatile than the broader market.

Protagonist Therapeutics has lower revenue, but higher earnings than Zai Lab. Zai Lab is trading at a lower price-to-earnings ratio than Protagonist Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zai Lab	$460.16M	6.54	-$175.54M	-$1.71	N/A
Protagonist Therapeutics	$46.02M	195.03	-$130.15M	$1.03	134.66

Protagonist Therapeutics has a net margin of 29.40% compared to Zai Lab's net margin of -41.86%. Protagonist Therapeutics' return on equity of 12.03% beat Zai Lab's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zai Lab	-41.86%	-27.43%	-16.72%
Protagonist Therapeutics	29.40%	12.03%	11.23%

Summary

Protagonist Therapeutics beats Zai Lab on 13 of the 17 factors compared between the two stocks.

How does Zai Lab compare to Kymera Therapeutics?

Zai Lab (NASDAQ:ZLAB) and Kymera Therapeutics (NASDAQ:KYMR) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, dividends, media sentiment, profitability, institutional ownership, analyst recommendations and risk.

41.7% of Zai Lab shares are held by institutional investors. 4.9% of Zai Lab shares are held by insiders. Comparatively, 16.0% of Kymera Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Zai Lab has a beta of 0.83, indicating that its share price is 17% less volatile than the broader market. Comparatively, Kymera Therapeutics has a beta of 1.96, indicating that its share price is 96% more volatile than the broader market.

Zai Lab has a net margin of -41.86% compared to Kymera Therapeutics' net margin of -285.33%. Kymera Therapeutics' return on equity of -21.22% beat Zai Lab's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zai Lab	-41.86%	-27.43%	-16.72%
Kymera Therapeutics	-285.33%	-21.22%	-19.21%

In the previous week, Kymera Therapeutics had 4 more articles in the media than Zai Lab. MarketBeat recorded 6 mentions for Kymera Therapeutics and 2 mentions for Zai Lab. Kymera Therapeutics' average media sentiment score of 0.81 beat Zai Lab's score of -0.14 indicating that Kymera Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zai Lab	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Kymera Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Zai Lab presently has a consensus target price of $37.25, suggesting a potential upside of 40.89%. Kymera Therapeutics has a consensus target price of $133.21, suggesting a potential upside of 15.36%. Given Zai Lab's higher probable upside, research analysts clearly believe Zai Lab is more favorable than Kymera Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zai Lab	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71
Kymera Therapeutics	1 Sell rating(s)	2 Hold rating(s)	22 Buy rating(s)	1 Strong Buy rating(s)	2.88

Zai Lab has higher revenue and earnings than Kymera Therapeutics. Kymera Therapeutics is trading at a lower price-to-earnings ratio than Zai Lab, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zai Lab	$460.16M	6.54	-$175.54M	-$1.71	N/A
Kymera Therapeutics	$105M	91.44	-$311.35M	-$3.24	N/A

Summary

Zai Lab and Kymera Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.

How does Zai Lab compare to Praxis Precision Medicines?

Zai Lab (NASDAQ:ZLAB) and Praxis Precision Medicines (NASDAQ:PRAX) are both mid-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, media sentiment, valuation, risk, earnings, dividends, analyst recommendations and institutional ownership.

41.7% of Zai Lab shares are held by institutional investors. Comparatively, 67.8% of Praxis Precision Medicines shares are held by institutional investors. 4.9% of Zai Lab shares are held by company insiders. Comparatively, 3.0% of Praxis Precision Medicines shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Zai Lab has a beta of 0.83, suggesting that its share price is 17% less volatile than the broader market. Comparatively, Praxis Precision Medicines has a beta of 2.76, suggesting that its share price is 176% more volatile than the broader market.

Zai Lab has higher revenue and earnings than Praxis Precision Medicines. Praxis Precision Medicines is trading at a lower price-to-earnings ratio than Zai Lab, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zai Lab	$460.16M	6.54	-$175.54M	-$1.71	N/A
Praxis Precision Medicines	N/A	N/A	-$303.27M	-$12.93	N/A

Zai Lab presently has a consensus price target of $37.25, suggesting a potential upside of 40.89%. Praxis Precision Medicines has a consensus price target of $612.42, suggesting a potential upside of 117.08%. Given Praxis Precision Medicines' stronger consensus rating and higher possible upside, analysts plainly believe Praxis Precision Medicines is more favorable than Zai Lab.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zai Lab	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71
Praxis Precision Medicines	2 Sell rating(s)	0 Hold rating(s)	15 Buy rating(s)	3 Strong Buy rating(s)	2.95

Praxis Precision Medicines has a net margin of 0.00% compared to Zai Lab's net margin of -41.86%. Zai Lab's return on equity of -27.43% beat Praxis Precision Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zai Lab	-41.86%	-27.43%	-16.72%
Praxis Precision Medicines	N/A	-34.15%	-32.42%

In the previous week, Praxis Precision Medicines had 1 more articles in the media than Zai Lab. MarketBeat recorded 3 mentions for Praxis Precision Medicines and 2 mentions for Zai Lab. Praxis Precision Medicines' average media sentiment score of 0.45 beat Zai Lab's score of -0.14 indicating that Praxis Precision Medicines is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zai Lab	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Praxis Precision Medicines	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Praxis Precision Medicines beats Zai Lab on 9 of the 16 factors compared between the two stocks.

Get Zai Lab News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ZLAB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ZLAB vs. The Competition

Export

Metric	Zai Lab	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$3.01B	$3.98B	$7.31B	$13.29B
Dividend Yield	N/A	3.63%	2.52%	12.57%
P/E Ratio	-15.46	13.88	274.08	25.69
Price / Sales	6.54	1,343.77	638.21	78.99
Price / Cash	N/A	113.29	77.80	52.76
Price / Book	4.14	15.40	10.47	6.32
Net Income	-$175.54M	-$22.82M	$3.49B	$359.73M
7 Day Performance	2.44%	-1.70%	-0.67%	0.17%
1 Month Performance	3.12%	-6.17%	-3.17%	-3.27%
1 Year Performance	-18.62%	30.67%	15.14%	5.58%

Zai Lab Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ZLAB Zai Lab	2.233 of 5 stars	$26.44 +0.1%	$37.25 +40.9%	-17.6%	$3.01B	$460.16M	N/A	1,784	News Coverage
KRYS Krystal Biotech	3.3169 of 5 stars	$336.68 -1.0%	$365.40 +8.5%	+107.2%	$10.06B	$389.13M	42.19	295	Positive News Analyst Forecast
ABVX Abivax	2.2207 of 5 stars	$106.66 -6.1%	$156.38 +46.6%	+14.8%	$9.91B	N/A	N/A	69	Trending News Earnings Report Analyst Forecast High Trading Volume
PTGX Protagonist Therapeutics	2.109 of 5 stars	$143.40 -3.0%	$147.13 +2.6%	+113.2%	$9.56B	$46.02M	139.22	141	Positive News
KYMR Kymera Therapeutics	1.9411 of 5 stars	$113.15 -1.3%	$131.63 +16.3%	+127.0%	$9.53B	$39.21M	N/A	273	Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ZLAB) was last updated on 9/24/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Zai Lab (ZLAB) Competitors

ZLAB vs. KRYS, ABVX, PTGX, KYMR, and PRAX

How does Zai Lab compare to Krystal Biotech?

Summary

How does Zai Lab compare to Abivax?

Summary

How does Zai Lab compare to Protagonist Therapeutics?

Summary

How does Zai Lab compare to Kymera Therapeutics?

Summary

How does Zai Lab compare to Praxis Precision Medicines?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ZLAB vs. The Competition

Zai Lab Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Zai Lab (ZLAB) Competitors

ZLAB vs. KRYS, ABVX, PTGX, KYMR, and PRAX

How does Zai Lab compare to Krystal Biotech?

Is KRYS or ZLAB more profitable?

Do analysts rate KRYS or ZLAB?

Do insiders and institutionals have more ownership in KRYS or ZLAB?

Does the media favor KRYS or ZLAB?

Which has more volatility & risk, KRYS or ZLAB?

Which has better valuation & earnings, KRYS or ZLAB?

Summary

How does Zai Lab compare to Abivax?

Does the media prefer ABVX or ZLAB?

Do analysts recommend ABVX or ZLAB?

Which has more volatility and risk, ABVX or ZLAB?

Do institutionals and insiders hold more shares of ABVX or ZLAB?

Is ABVX or ZLAB more profitable?

Which has better earnings & valuation, ABVX or ZLAB?

Summary

How does Zai Lab compare to Protagonist Therapeutics?

Do institutionals & insiders hold more shares of ZLAB or PTGX?

Do analysts prefer ZLAB or PTGX?

Does the media refer more to ZLAB or PTGX?

Which has more volatility and risk, ZLAB or PTGX?

Which has better valuation and earnings, ZLAB or PTGX?

Is ZLAB or PTGX more profitable?

Summary

How does Zai Lab compare to Kymera Therapeutics?

Do insiders and institutionals hold more shares of ZLAB or KYMR?

Which has more risk & volatility, ZLAB or KYMR?

Is ZLAB or KYMR more profitable?

Does the media refer more to ZLAB or KYMR?

Do analysts recommend ZLAB or KYMR?

Which has higher valuation and earnings, ZLAB or KYMR?

Summary

How does Zai Lab compare to Praxis Precision Medicines?

Do institutionals and insiders have more ownership in ZLAB or PRAX?

Which has more volatility & risk, ZLAB or PRAX?

Which has stronger valuation and earnings, ZLAB or PRAX?

Do analysts rate ZLAB or PRAX?

Is ZLAB or PRAX more profitable?

Does the media refer more to ZLAB or PRAX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ZLAB vs. The Competition

Zai Lab Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools